Wall Street brokerages forecast that MAXIMUS, Inc. (NYSE:MMS) will post sales of $766.17 million for the current quarter, Zacks reports. Four analysts have provided estimates for MAXIMUS’s earnings, with the lowest sales estimate coming in at $753.80 million and the highest estimate coming in at $774.64 million. MAXIMUS reported sales of $612.79 million during the same quarter last year, which indicates a positive year over year growth rate of 25%. The firm is scheduled to report its next earnings results on Thursday, May 9th.
According to Zacks, analysts expect that MAXIMUS will report full year sales of $2.96 billion for the current financial year, with estimates ranging from $2.94 billion to $2.97 billion. For the next financial year, analysts expect that the firm will report sales of $3.18 billion, with estimates ranging from $3.04 billion to $3.31 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for MAXIMUS.
MAXIMUS (NYSE:MMS) last released its quarterly earnings data on Thursday, February 7th. The health services provider reported $0.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.80 by $0.06. MAXIMUS had a return on equity of 20.09% and a net margin of 8.94%. The business had revenue of $664.60 million during the quarter, compared to analyst estimates of $672.08 million. During the same quarter in the previous year, the firm posted $0.89 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year.
MMS has been the subject of a number of analyst reports. Zacks Investment Research lowered MAXIMUS from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. ValuEngine lowered MAXIMUS from a “buy” rating to a “hold” rating in a research report on Thursday, February 28th.
In other MAXIMUS news, Director Russell A. Beliveau sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $64.14, for a total transaction of $64,140.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman Richard A. Montoni sold 35,000 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $70.97, for a total value of $2,483,950.00. Following the transaction, the insider now owns 412,874 shares of the company’s stock, valued at approximately $29,301,667.78. The disclosure for this sale can be found here. Insiders have sold a total of 54,715 shares of company stock valued at $3,866,689 in the last quarter. 2.20% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP acquired a new position in shares of MAXIMUS in the 3rd quarter worth approximately $254,000. American Century Companies Inc. boosted its stake in MAXIMUS by 131.2% during the third quarter. American Century Companies Inc. now owns 238,436 shares of the health services provider’s stock worth $15,513,000 after acquiring an additional 135,314 shares in the last quarter. Stone Ridge Asset Management LLC boosted its stake in MAXIMUS by 14.8% during the third quarter. Stone Ridge Asset Management LLC now owns 32,933 shares of the health services provider’s stock worth $2,143,000 after acquiring an additional 4,252 shares in the last quarter. Bessemer Group Inc. boosted its stake in MAXIMUS by 2.9% during the third quarter. Bessemer Group Inc. now owns 35,697 shares of the health services provider’s stock worth $2,323,000 after acquiring an additional 997 shares in the last quarter. Finally, ING Groep NV boosted its stake in MAXIMUS by 42.2% during the third quarter. ING Groep NV now owns 9,820 shares of the health services provider’s stock worth $639,000 after acquiring an additional 2,913 shares in the last quarter. Institutional investors own 94.42% of the company’s stock.
NYSE:MMS traded down $0.02 during midday trading on Wednesday, reaching $71.21. 328,776 shares of the company traded hands, compared to its average volume of 367,623. MAXIMUS has a twelve month low of $60.00 and a twelve month high of $73.81. The firm has a market capitalization of $4.52 billion, a P/E ratio of 20.94, a P/E/G ratio of 1.93 and a beta of 0.97. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.32 and a quick ratio of 2.32.
The firm also recently declared a quarterly dividend, which was paid on Thursday, February 28th. Shareholders of record on Friday, February 15th were given a dividend of $0.25 per share. The ex-dividend date was Thursday, February 14th. This represents a $1.00 dividend on an annualized basis and a yield of 1.40%. MAXIMUS’s dividend payout ratio (DPR) is presently 29.41%.
MAXIMUS Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs worldwide. The company's Health Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews.
See Also: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.